Main article: Ordering olmesartan
Olmesartan medoxomil is often referred by its brand name equivalent, Benicar. Patients on the Marshall Protocol (MP) take 40mg of olmesartan four to six times daily. There is no substitute for olmesartan.
Insurance coverage for olmesartan varies. Some patients obtain their olmesartan through online pharmacies.
There is no substitute for olmesartan (Benicar). Patients are warned not to order Benicar HCT, which contains a diuretic.
Olmesartan is both a potent anti-inflammatory and a Vitamin D Receptor agonist, qualities which make the medication indispensable to patients on the Marshall Protocol (MP). Olmesartan has proven a safe therapeutic in a range of conditions.
Brand name olmesartan, which is manufactured by Daiichi Sankyo, Inc., is usually more expensive than generic olmesartan. The Benicar manufactured by Sankyo has an identification stamp on the tablet saying “C15” for the 40mg tablets or “C14” for the 20mg tablets. The stamp “Sankyo” is on the other side of these tablets.
Based on patient response, there is no evidence to indicate that Olmecip or any other generic is inferior. Olmecip smells differently, but this is due to it having a different binder formulation than the olmesartan made by Sankyo. Also, Olmecip dissolves more quickly, a benefit for MP patients when using frequent dosing.
Do not order Benicar HCT, also known as Benicar Hydrochlorothiazide. Thiazides are diuretics and contraindicated on the MP. Benicar HCT is orange. Benicar without HCT is white.
Main article: Dosing and administration of olmesartan
It is imperative that patients on the Marshall Protocol (MP) take regular doses of olmesartan (the brand name of which is Benicar), a medication for which there is no substitute. Olmesartan has an highly safe track record. MP patients are required to take 40mg of olmesartan every six hours – that is, equally spaced doses, four times a day – with or without food. Patients who take olmesartan once a day are not doing the MP. Do not ramp or gradually increase olmesartan.
In cases where a dose is missed, patients may take an extra olmesartan as soon as possible and/or sublingually. When severe immunopathology strikes or in the case of an acute emergency, patients may increase the frequency of olmesartan to up to six times day. Another option is to take a dose of 60mg.
MP patients may want to keep at least one month of extra olmesartan on hand.
Main article: Patient response to olmesartan
Olmesartan (Benicar) has two actions. It palliates symptoms by reducing inflammation, and it activates the innate immune response. Patients who begin the Marshall Protocol (MP) may experience either, both, or neither. According to one rough estimate, 25% of patients who begin the MP experience immediate symptomatic relief when they begin the olmesartan blockade, about 25% feel no different, and the other 50% will experience some adjustment symptoms. Even for MP patients who have a minimal initial reaction to olmesartan, the medication almost always ultimately has strong antibacterial effects resulting in immunopathology. For olmesartan to be effective, it has to be dosed regularly: 40mg every 6-8 hours.
The question of how much olmesartan (Benicar) to keep on hand requires consideration of a couple of factors. Patients who order their Benicar from overseas may want to plan for their medication to take up to a month to arrive. Delays in insurance coverage – for example, while awaiting appeal – can take even longer. Generally speaking, it helps to have at least one month of Benicar on hand.
In the event a patient runs out, it may be worth asking if one's doctor has Benicar samples as many do.
Also, patients who get their Benicar through insurance should refill their Benicar as soon as allowed. This will provide a patient with a few extra pills each refill.
Main article: Science behind olmesartan
Patients on the Marshall Protocol (MP) take olmesartan (Benicar), a drug whose actions are well known, every six hours. A growing body of research supports the use of olmesartan as a part of a curative therapy for chronic disease. In general, olmesartan tends to be prescribed for its antihypertensive properties due to the fact that is an angiotensin receptor blocker.
For the purposes of the MP, olmesartan has two primary actions: it reduces inflammation by blocking the Nuclear Factor-kappaB cytokine pathway and it is an agonist of the Vitamin D Receptor (VDR). As a VDR agonist, olmesartan activates the innate immune response. Research supports the safety of the doses used by MP patients. Olmesartan has minimal interactions with other drugs and is one of the safest drugs on the market.
Main article: Olmesartan and kidney disease
There is a tendency for some physicians to become alarmed by these fluctuations, particularly if a patient has kidney disease. However, for the vast majority of patients these test results are an expected part of the healing process. In fact, a wide range of research shows that olmesartan is therapeutic for kidney disease.
Main article: Safety of olmesartan
Some patients and healthcare providers have expressed concerns about the safety of higher than typical doses of olmesartan (Benicar).
Ample research supports the fact that olmesartan is one of the safest and has the most gentle side effects profiles of almost any drug on the market – as opposed to Benicar HCT, which contains a thiazide and is harmful.
I feel there are simply no adverse reactions or negative side effects that I need to worry about while taking the Marshall Protocol medications. It is an extremely safe approach. Personally, I believe overtreating this condition is preferable than undertreating as the side effects of both antibiotics and Benicar are so minimal compared to the risk of [disease] recurrence.
Greg Blaney, M.D.
Sankyo put the medoxomil radical on Olmesartan in order to slow its absorption, so it could be dosed once a day. That is not what we need for the MP, we want it to go to work as quickly as possible. They also said that Pure Olmesartan was not absorbed as well as Olmesartan medoxomil, but that turned out to be because the flora in a Mouse gut converted most of the Olmesartan to Olmesartan Glucuronide. When we tested in Homo sapiens, that was not so much a problem, and the Pure Olmesartan is more effective at both immune activation, and palliation, when used as we do in the MP :)
Oral Pure Olmesartan reaches its peak concentration at about one hour, and it therefore achieves a higher level peak than achievable with OM, as that absorbs more slowly. A high peak is the best way to bump ligands out of any receptors… It is also the best way to get palliation soon after you feel you need it, eg, when you have forgotten a dose…
There seems to be a limit on OM absorption, and it varies from person to person. An enzyme from Pseudomonas, or its homologue, is necessary for converting OM to O+M, and this may not be present in unlimited quantities in everybody's gut. the PO is just absorbed through the intestine wall intact (a little is degraded to Olmesartan Glucuronide with both OM and PO).
You cannot adjust the dosing and/or frequency of OM and achieve what PO can do…
The VDR often doesn't need antibiotics to help the immune system recognize the microbiota, especially when pure olmesartan is used. Only use antibiotics when an increased level of immunopathology is desired :)
Olmecip 40 tablets Ingredients Active Olmesartan Medoxomil INH Inactive Lactose IP (Lactose Monohydrate 200 mesh) Croscarmellose Sodium NF Hydroxy propyl cellulose Klucel LF Microcrystalline cellulose Purified talc Croscarmellose sodium Stearic acid Opadry II 33G28707 white